Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited naming Colm Burke .
Filed returns
55
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Hanover Media Strategy Limited | Health | Discussion of proposed Early Access Programme of innovative oncology medicines (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Hanover Media Strategy Limited | Health | Discussion of proposed Early Access Programme for innovative oncology medicines. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Hanover Media Strategy Limited | Health | Briefing on the school flu vaccine rollout in the context of a forthcoming Joint Committee on Health hearing on vaccine policy (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | Letter to Joint Committee on Health concerning the current inequities in access to innovative oncology medicines in Ireland. (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | AV Room Briefing Event to discuss a Proposal for an Early Access Programme for Innovative Oncology Medicines (Public policy or programme) | 41 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Children and Youth Affairs | Meeting request to discuss Tigers Childcare's Pre Budget 2026 Submission (Public policy or programme) | 44 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | Meeting request to discuss protection for over 65s in winter flu season (Public policy or programme) | 33 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Children and Youth Affairs | AV Room Briefing Event to discuss the ongoing crises facing the early years and childcare sector (Public policy or programme) | 29 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Health | Meeting request to discuss protection for over 65s in winter flu season (Public policy or programme) | 19 | On lobbying.ie |
| Jan–Apr 2025 | Hanover Media Strategy Limited | Health | Rare Disease & Life Sciences Policy (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | AstraZeneca health policy priorities for the new Programme for Government (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | Life Sciences Strategy for Ireland (Public policy or programme) | 10 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | To share information on the level of vaccine protection for the over 65s population in Ireland (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Engagement with members of the health committee in advance of debate on rare diseases (Public policy or programme) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Chronic kidney disease in Ireland: recommendations to improve health outcomes for chronic kidney disease patients and reduce healthcare costs. (Matters involving public funds) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Transport | Correspondence regarding the Taxi Supply Shortage (Public policy or programme) | 44 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 23 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | The landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Request for a meeting to discuss the landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 18 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Rare Disease Policy (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 9 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 9 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Provided update to select politicians on developments in Oncology therapies and barriers to access (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 5 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 10 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 8 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 13 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) | 12 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Telehealth policy in Ireland (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) | 16 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 52 | 94.5% | |
| Children and Youth Affairs | 2 | 3.6% | |
| Transport | 1 | 1.8% |